Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
67.8 (1y: +28%)
Market Cap P/E(ttm)
Enterprise Value P/B
FMCMF- OTCPK (USA)
Fresenius Medical Care AG & Co. KGaA
Not Rated
Top Ranked Predictable Companies
$67.80
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt 0.066
FMCMF's Cash to Debt is ranked lower than
806451% of the 124 Companies
in the Global Medical Care industry.

( Industry Median: 0.24 vs. FMCMF: 0.066 )
FMCMF' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.07
Interest Coverage 5.7
FMCMF's Interest Coverage is ranked lower than
961538% of the 104 Companies
in the Global Medical Care industry.

( Industry Median: 6.50 vs. FMCMF: 5.7 )
FMCMF' s 10-Year Interest Coverage Range
Min: -2   Max: No Debt
Current: 5.7
-2
No Debt
F-Score: 5
Z-Score: 1.19
M-Score: -2.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) 17.20
FMCMF's Operating margin (%) is ranked lower than
952380% of the 105 Companies
in the Global Medical Care industry.

( Industry Median: 10.90 vs. FMCMF: 17.20 )
FMCMF' s 10-Year Operating margin (%) Range
Min: -8.4   Max: 17.7
Current: 17.2
-8.4
17.7
Net-margin (%) 8.4
FMCMF's Net-margin (%) is ranked lower than
1041666% of the 96 Companies
in the Global Medical Care industry.

( Industry Median: 6.20 vs. FMCMF: 8.4 )
FMCMF' s 10-Year Net-margin (%) Range
Min: -9.2   Max: 11.4
Current: 8.4
-9.2
11.4
ROE (%) 14
FMCMF's ROE (%) is ranked lower than
1052631% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 10.30 vs. FMCMF: 14 )
FMCMF' s 10-Year ROE (%) Range
Min: -18   Max: 17.6
Current: 14
-18
17.6
ROA (%) 5.2
FMCMF's ROA (%) is ranked lower than
1041666% of the 96 Companies
in the Global Medical Care industry.

( Industry Median: 5.30 vs. FMCMF: 5.2 )
FMCMF' s 10-Year ROA (%) Range
Min: -7.2   Max: 6.8
Current: 5.2
-7.2
6.8
ROC (Joel Greenblatt) (%) 42.40
FMCMF's ROC (Joel Greenblatt) (%) is ranked lower than
999999% of the 100 Companies
in the Global Medical Care industry.

( Industry Median: 25.50 vs. FMCMF: 42.40 )
FMCMF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -29.2   Max: 102.8
Current: 42.4
-29.2
102.8
Revenue Growth (%) 4.3
FMCMF's Revenue Growth (%) is ranked lower than
1612902% of the 62 Companies
in the Global Medical Care industry.

( Industry Median: 6.00 vs. FMCMF: 4.3 )
FMCMF' s 10-Year Revenue Growth (%) Range
Min: 4.3   Max: 11.8
Current: 4.3
4.3
11.8
EBITDA Growth (%) 5.4
FMCMF's EBITDA Growth (%) is ranked lower than
2325579% of the 43 Companies
in the Global Medical Care industry.

( Industry Median: 8.30 vs. FMCMF: 5.4 )
FMCMF' s 10-Year EBITDA Growth (%) Range
Min: 5.4   Max: 15.2
Current: 5.4
5.4
15.2
ยป FMCMF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with FMCMF



No Insider Trades Found!

Preferred stocks of Fresenius Medical Care AG & Co. KGaA

SymbolPriceYieldDescription
FMCMF67.800.00
FME3.Germany52.940.98
FMSPR9.771.12ADR

Ratios

vs
industry		 vs
history
EV-to-EBIT 11.2
FMCMF's EV-to-EBIT is ranked lower than
862068% of the 116 Companies
in the Global Medical Care industry.

( Industry Median: 14.10 vs. FMCMF: 11.2 )
FMCMF' s 10-Year EV-to-EBIT Range
Min: 11.4   Max: 95.9
Current: 11.2
11.4
95.9

Valuation & Return

vs
industry		 vs
history
Earnings Yield (Greenblatt) 8.90
FMCMF's Earnings Yield (Greenblatt) is ranked lower than
854700% of the 117 Companies
in the Global Medical Care industry.

( Industry Median: 7.10 vs. FMCMF: 8.90 )
FMCMF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 10.7
Current: 8.9
1
10.7

Business Description

Fresenius Medical Care AG & Co. KGaA was originally incorporated on August 5, 1996. It is a kidney dialysis company, operating in both the field of dialysis products and the field of dialysis services. The Company's dialysis business is vertically integrated, providing dialysis treatment at its own dialysis clinics and supplying these clinics with a range of products. In addition, it sells dialysis products to other dialysis service providers. It also develops and manufactures a full range of equipment, systems and disposable products, which it sells to customers in over 115 countries. It offers life-maintaining and life-saving dialysis services and products in a market which is characterized by a favorable demographic development. It provides expanded and enhanced patient services, including renal pharmaceutical products and laboratory services, to both its own clinics and those of third parties. The Company has developed disease state management methodologies, which involve the coordination of holistic patient care for ESRD patients and which are attractive to managed care payors. It provides ESRD and chronic kidney disease management programs to about 4,000 patients. The Company's clinics also offer services for home dialysis patients, the majority of whom receive peritoneal dialysis treatment. It also provides dialysis services under contract to hospitals in the U.S. on an 'as needed' basis for hospitalized ESRD patients and for patients suffering from acute kidney failure. It provides laboratory testing and marketing services in the U.S. through Spectra Laboratories (Spectra). Spectra provides blood, urine and other bodily fluid testing services to determine the appropriate individual dialysis therapy for a patient and to assist physicians in determining whether a dialysis patient's therapy regimen, diet and medicines remain optimal. The UltraCare(r) program of its North America dialysis services group represents its commitment to deliver excellent care to patients through innovative programs, state-of-the art technology, continuous quality improvement and a focus on superior patient service. The Company's main trademarks are the name 'Fresenius' and the 'F' logo'. The Company's competitors in the sale of hemodialysis and peritoneal dialysis products include Gambro AB, Baxter International Inc., Asahi Kasei Kuraray Medical Co. Ltd., Bellco S.r.l., B. Braun Melsungen AG, Nipro Corporation Ltd., Nikkiso Co., Ltd., Terumo Corporation, Kawasumi Laboratories Inc., Fuso Pharmaceuticals Industries Ltd., and Toray Industries, Inc. The Company's operations are subject to extensive governmental regulation by virtually every country in which it operates including, most notably, in the U.S., at the federal, state and local levels.
Company Website
Industry: Medical Care
Compare:
Traded in other countries:FMS.USA, FMEA.Germany, FME.Germany, FMEN.Germany, FME3.Germany, FMSPR.USA

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial